Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2018 May 1;75(5):548-556.
doi: 10.1001/jamaneurol.2017.4907.

Association Between Amyloid and Tau Accumulation in Young Adults With Autosomal Dominant Alzheimer Disease

Yakeel T Quiroz  1   2 , Reisa A Sperling  1   3   4 , Daniel J Norton  1 , Ana Baena  2 , Joseph F Arboleda-Velasquez  5 , Danielle Cosio  1   6 , Aaron Schultz  1   3 , Molly Lapoint  1   3 , Edmarie Guzman-Velez  1 , John B Miller  7 , Leo A Kim  5   7 , Kewei Chen  8 , Pierre N Tariot  8 , Francisco Lopera  2 , Eric M Reiman  8 , Keith A Johnson  1   4
Affiliations
Multicenter Study

Association Between Amyloid and Tau Accumulation in Young Adults With Autosomal Dominant Alzheimer Disease

Yakeel T Quiroz et al. JAMA Neurol. .

Abstract

Importance: It is critically important to improve our ability to diagnose and track Alzheimer disease (AD) as early as possible. Individuals with autosomal dominant forms of AD can provide clues as to which and when biological changes are reliably present prior to the onset of clinical symptoms.

Objective: To characterize the associations between amyloid and tau deposits in the brains of cognitively unimpaired and impaired carriers of presenilin 1 (PSEN1) E280A mutation.

Design, setting, and participants: In this cross-sectional imaging study, we leveraged data from a homogeneous autosomal dominant AD kindred, which allowed us to examine measurable tau deposition as a function of individuals' proximity to the expected onset of dementia. Cross-sectional measures of carbon 11-labeled Pittsburgh Compound B positron emission tomography (PET) and flortaucipir F 18 (previously known as AV 1451, T807) PET imaging were assessed in 24 PSEN1 E280A kindred members (age range, 28-55 years), including 12 carriers, 9 of whom were cognitively unimpaired and 3 of whom had mild cognitive impairment, and 12 cognitively unimpaired noncarriers.

Main outcomes and measures: We compared carbon 11-labeled Pittsburgh Compound B PET cerebral with cerebellar distribution volume ratios as well as flortaucipir F 18 PET cerebral with cerebellar standardized uptake value ratios in mutation carriers and noncarriers. Spearman correlations characterized the associations between age and mean cortical Pittsburgh Compound B distribution volume ratio levels or regional flortaucipir standardized uptake value ratio levels in both groups.

Results: Of the 24 individuals, the mean (SD) age was 38.0 (7.4) years, or approximately 6 years younger than the expected onset of clinical symptoms in carriers. Compared with noncarriers, cognitively unimpaired mutation carriers had elevated mean cortical Pittsburgh Compound B distribution volume ratio levels in their late 20s, and 7 of 9 carriers older than 30 years reached the threshold for amyloidosis (distribution volume ratio level > 1.2). Elevated levels of tau deposition were seen within medial temporal lobe regions in amyloid-positive mutation carriers 6 years before clinical onset of AD in this kindred. Substantial tau deposition in the neocortex was only observed in 1 unimpaired carrier and in those with mild cognitive impairment. β-Amyloid uptake levels were diffusely elevated in unimpaired carriers approximately 15 years prior to expected onset of mild cognitive impairment. In carriers, higher levels of tau deposition were associated with worse performance on the Mini-Mental State Examination (entorhinal cortex: r = -0.60; P = .04; inferior temporal lobe: r = -0.54; P = .06) and the Consortium to Establish a Registry for Alzheimer Disease Word List Delayed Recall (entorhinal cortex: r = -0.86; P < .001; inferior temporal lobe: r = -0.70; P = .01).

Conclusions and relevance: The present findings add to the growing evidence that molecular markers can characterize biological changes associated with AD in individuals who are still cognitively unimpaired. The findings also suggest that tau PET imaging may be useful as a biomarker to distinguish individuals at high risk to develop the clinical symptoms of AD and to track disease progression.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Disclosures: Dr Quiroz was supported by grants 1200-228010 and 1200-228767 from the Massachusetts General Hospital Executive Committee on Research. Dr Sperling receives research support from grants U01 AG032438, U01 AG024904, R01 AG037497, R01 AG034556, and U19 AG010483 from the National Institutes of Health. She is a site principal investigator or coinvestigator for Avid, Bristol-Myers Squibb, Pfizer, and Janssen Alzheimer Immunotherapy clinical trials. Dr Tariot has provided consulting services for Abbott Laboratories, AbbVie, AC Immune, Boehringer-Ingelheim, California Pacific Medical Center, Chase Pharmaceuticals, CME Inc, Medavante, Otsuka, Sanofi-Aventis, Eli Lilly and Company, AstraZeneca, Avanir, Bristol-Myers Squibb, Cognoptix, Janssen, Merck and Company, and Roche; has received research support from AstraZeneca, Avanir, Bristol-Myers Squibb, Cognoptix, Janssen, Merck and Company, Roche, Baxter, Functional Neuromodulation, GE Healthcare, Genentech, Pfizer, Targacept, Avid Radiopharmaceuticals, the National Institute on Aging, and the Arizona Department of Health Services; owns stock options in Adamas Pharmaceuticals; and has contributed to a patent for biomarkers of Alzheimer disease owned by the University of Rochester. Dr Reiman has received research funding from AVID and has served as a paid consultant for Eli Lilly. Dr Johnson has provided consulting services for Lilly, Novartis, Janssen, Roche, Piramal, GE Healthcare, Siemens, ISIS Pharma, AZTherapy, and Biogen; has received support from a joint National Institutes of Health– and Lilly-sponsored clinical trial (Anti-Amyloid Treatment in Asymptomatic Alzheimer’s [A4] Study); and has received research support from the National Institute on Aging (grants U19AG10483 and U01AG024904-S1), Fidelity Biosciences, the Michael J. Fox Foundation, and the Alzheimer’s Association. No other disclosures were reported.

Figures

Figure 1.
Figure 1.. Spatial Patterns of Carbon 11–Labeled Pittsburgh Compound B (PiB) Positron Emission Tomography (PET) and Flortaucipir F 18 (FTP) PET Binding in Presenilin 1 E280A Mutation Carriers
Coronal and sagittal PiB PET distribution volume ratio (DVR) maps are shown on the left, and coronal and sagittal FTP PET standardized uptake value ratio (SUVR) maps are presented on the right. Images are displayed in standardized atlas space, along with whole-brain surface renderings, with a left hemisphere view. A, An unimpaired noncarrier in their early 40s with low β-amyloid (Aβ) levels and low FTP binding in the inferior temporal cortex. B, An unimpaired mutation carrier in their late 20s with low Aβ levels and low FTP binding in the inferior temporal cortex. C, An unimpaired mutation carrier in their early 30s with higher Aβ levels and low, nonspecific FTP binding in the inferior temporal lobe. D, An unimpaired mutation carrier in their late 30s with high Aβ and tau levels with FTP binding in the inferior temporal and parietal cortices. E, An impaired mutation carrier in their early 40s with mild cognitive impairment with high Aβ levels and extensive FTP binding in the temporal, parietal, and frontal cortices. Elevated levels of FTP binding are evident within medial temporal lobe regions in amyloid-positive mutation carriers within 10 years of estimated years to symptom onset. Substantial FTP binding in the neocortex is evident in mutation carriers with the highest levels of Aβ.
Figure 2.
Figure 2.. Comparison of Spatial Distribution of Flortaucipir F 18 Binding Between the 12 Presenilin 1 Carriers and the 12 Noncarriers
The threshold of significance was P < .001.
Figure 3.
Figure 3.. Relations Among Flortaucipir F 18 (FTP) Standardized Uptake Value Ratios (SUVRs) and Related Variables in Presenilin 1 Mutation Carriers and Noncarriers
A, Tau and β-amyloid (Aβ) levels as a function of age. B, Tau level as a function of Aβ level. C, Cognition as a function of tau level. Open circles indicate noncarriers from the PSEN1 kindred, light blue circles indicate PSEN1 amyloid-negative mutation carriers (distribution volume ratio [DVR] < 1.2), and dark blue circles indicate PSEN1 amyloid-positive mutation carriers (DVR > 1.2). A single carrier had a DVR level of 1.195 and is shown as a dark blue circle, despite being amyloid negative according to convention. Linear fit lines are shown for carriers and noncarriers separately to aid inspection. CERAD indicates Consortium to Establish a Registry for Alzheimer Disease; DVR, distribution volume ratio; MMSE, Mini-Mental State Examination; PiB, Pittsburgh Compound B.
See this image and copyright information in PMC

Dataset use reported in

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Iqbal K, Grundke-Iqbal I. Neurofibrillary pathology leads to synaptic loss and not the other way around in Alzheimer disease. J Alzheimers Dis. 2002;4(3):235-238. - PubMed
    1. Crews L, Masliah E. Molecular mechanisms of neurodegeneration in Alzheimer’s disease. Hum Mol Genet. 2010;19(R1):R12-R20. - PMC - PubMed
    1. Arnold SE, Hyman BT, Flory J, Damasio AR, Van Hoesen GW. The topographical and neuroanatomical distribution of neurofibrillary tangles and neuritic plaques in the cerebral cortex of patients with Alzheimer’s disease. Cereb Cortex. 1991;1(1):103-116. - PubMed
    1. Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 1991;82(4):239-259. - PubMed
    1. Lopera F, Ardilla A, Martínez A, et al. . Clinical features of early-onset Alzheimer disease in a large kindred with an E280A presenilin-1 mutation. JAMA. 1997;277(10):793-799. - PubMed

Publication types

MeSH terms